Xtant Medical

News

Xtant Medical Postpones Release of Third Quarter 2017 Financial Results

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017. The Company now plans to release its third quarter 2017 financial results in conjunction with t…
Read more

Xtant Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform™ to Market

BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio.  Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Ph…
Read more

Xtant Medical to Announce Third Quarter 2017 Results on Wednesday, November 8th 

BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 8th, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Int…
Read more

Xtant Medical to Feature Product Portfolio at the 2017 North American Spine Society Annual Meeting

BELGRADE, Mont., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced it will be showcasing its portfolio, featuring new technologies, at the 2017 annual North American Spine Society (NASS) Annual Meeting in Orlando, FL.  Xtant will have a technical exhibit booth located at #1118, and will be hosting a cadaveric product demonstration highlighting proprietary hardware a…
Read more

Xtant Medical Announces Consolidation of Fixation Operations to Montana and Closure of Dayton Facility

Expected approximate $2 million savings when implemented BELGRADE, Mont., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the closure of its Dayton, Ohio facility and the transitioning of its fixation operations to the Company’s headquarters in Belgrade, Montana. This decision will allow the Company to align operations with the current and future needs of i…
Read more

Xtant Medical Receives 510k Clearance for Expanded Indications of Irix-A

BELGRADE, Mont., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Irix-A interbody spacer.  The clearance provides for the addition of three additional size configurations for an expanded market opportunity, and importantly, for use with allograft.  This clearance i…
Read more

Xtant Medical Reports Second Quarter 2017 Financial Results

Company Continues to Take Steps During Restructuring to Build for Future Growth BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the quarter ended June 30th, 2017. The Company reported Second Quarter 2017 revenue of approximately $21.4 million and an EBITDA loss of approximately ($2.1) million for the period. Reven…
Read more

Xtant Medical Receives FDA Clearance for Calix-C Cervical Interbody Line Extension and Expanded Indications

BELGRADE, Mont., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared product line extensions for the Calix-C family of cervical interbody cages.  The clearance provides for the addition of two larger footprints and importantly, for use with allograft.  This clearance strengthens Xtant Medical’s focu…
Read more

Xtant Medical Joins the 2018 Donate Life Rose Parade Float to Highlight the Power of Organ, Eye, and Tissue Donation

BELGRADE, Mont., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, is proud to announce its sponsorship of the 2018 Donate Life float at the January 1 Rose Parade® in Pasadena. The Donate Life float, now in its 15th year, is part of a national effort of more than 50 organizations that have teamed up to deliver the simple, life giving message that the kind and generous act…
Read more

Xtant Medical to Announce Second Quarter 2017 Results on August 9th, 2017

BELGRADE, Mont., July 24, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 9, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chief Financial …
Read more

Xtant Medical Announces Rescheduling of Annual Meeting

BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the Company's annual meeting of stockholders, originally scheduled for June 21, 2017, to a later date, as the Company continues to evaluate its strategic alternatives. The Company will announce a new annual meeting date and record date when they are deter…
Read more

Xtant Medical Enters into Licensing Agreement for Sites Medical’s OsteoSync Ti Technology

BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC, for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. "We are very excited to work with Sites Medical," said Carl O'Connell, CEO of Xtant Medical.…
Read more